Mast cell sarcoma: Clinical management

Catherine R. Weiler; Joseph Butterfield

doi:10.1016/j.iac.2014.01.004

Mast cell sarcoma: Clinical management

Catherine R. Weiler, Joseph Butterfield

Allergic Diseases

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Mast cell sarcoma is a disorder that results in abnormal mast cells as identified by morphology, special stains, and in some publications, c-kit mutation analysis. It affects animal species such as canines more commonly than humans. In humans it is a very rare condition, with variable clinical presentation. There is no standard therapy for the disorder. It can affect any age group. It is occasionally associated with systemic mastocytosis and/or urticaria pigmentosa. The prognosis of mast cell sarcoma in published literature is very poor in humans.

Original language	English (US)
Pages (from-to)	423-432
Number of pages	10
Journal	Immunology and Allergy Clinics of North America
Volume	34
Issue number	2
DOIs	https://doi.org/10.1016/j.iac.2014.01.004
State	Published - May 2014

Keywords

Clinical presentation of mast cell sarcoma
Mast cell sarcoma
Mastocytosis
Prognosis of mast cell sarcoma
Treatment of mast cell sarcoma

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.iac.2014.01.004

Cite this

@article{94527ce48e4d477daa78254d584a6d98,

title = "Mast cell sarcoma: Clinical management",

abstract = "Mast cell sarcoma is a disorder that results in abnormal mast cells as identified by morphology, special stains, and in some publications, c-kit mutation analysis. It affects animal species such as canines more commonly than humans. In humans it is a very rare condition, with variable clinical presentation. There is no standard therapy for the disorder. It can affect any age group. It is occasionally associated with systemic mastocytosis and/or urticaria pigmentosa. The prognosis of mast cell sarcoma in published literature is very poor in humans.",

keywords = "Clinical presentation of mast cell sarcoma, Mast cell sarcoma, Mastocytosis, Prognosis of mast cell sarcoma, Treatment of mast cell sarcoma",

author = "Weiler, {Catherine R.} and Joseph Butterfield",

note = "Funding Information: The authors have no disclosures and no conflicts of interest. Dr J. Butterfield and Dr C.R. Weiler are funded by Mayo Clinic Rochester . Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "2014",

month = may,

doi = "10.1016/j.iac.2014.01.004",

language = "English (US)",

volume = "34",

pages = "423--432",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Mast cell sarcoma

T2 - Clinical management

AU - Weiler, Catherine R.

AU - Butterfield, Joseph

N1 - Funding Information: The authors have no disclosures and no conflicts of interest. Dr J. Butterfield and Dr C.R. Weiler are funded by Mayo Clinic Rochester . Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 2014/5

Y1 - 2014/5

N2 - Mast cell sarcoma is a disorder that results in abnormal mast cells as identified by morphology, special stains, and in some publications, c-kit mutation analysis. It affects animal species such as canines more commonly than humans. In humans it is a very rare condition, with variable clinical presentation. There is no standard therapy for the disorder. It can affect any age group. It is occasionally associated with systemic mastocytosis and/or urticaria pigmentosa. The prognosis of mast cell sarcoma in published literature is very poor in humans.

AB - Mast cell sarcoma is a disorder that results in abnormal mast cells as identified by morphology, special stains, and in some publications, c-kit mutation analysis. It affects animal species such as canines more commonly than humans. In humans it is a very rare condition, with variable clinical presentation. There is no standard therapy for the disorder. It can affect any age group. It is occasionally associated with systemic mastocytosis and/or urticaria pigmentosa. The prognosis of mast cell sarcoma in published literature is very poor in humans.

KW - Clinical presentation of mast cell sarcoma

KW - Mast cell sarcoma

KW - Mastocytosis

KW - Prognosis of mast cell sarcoma

KW - Treatment of mast cell sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84898829229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898829229&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2014.01.004

DO - 10.1016/j.iac.2014.01.004

M3 - Review article

C2 - 24745684

AN - SCOPUS:84898829229

SN - 0889-8561

VL - 34

SP - 423

EP - 432

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 2

ER -

Mast cell sarcoma: Clinical management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this